Stock 600420 SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

News Shanghai Shyndec Pharmaceutical Co., Ltd.

Equities

600420

CNE000001JG2

End-of-day quote Shanghai S.E.
Other stock markets
 03:30:00 26/04/2024 am IST 		5-day change 1st Jan Change
10.61 CNY -0.66% Intraday chart for Shanghai Shyndec Pharmaceutical Co., Ltd. +1.14% +8.38%
16/04 Shyndec Pharmaceutical's Unit Gets Nod to Market Empagliflozin Tablets MT
15/04 China stocks rise after new guidelines; HK shares drop RE

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Shyndec Pharmaceutical's Unit Gets Nod to Market Empagliflozin Tablets
MT
China stocks rise after new guidelines; HK shares drop
RE
Chinese FDA Grants Marketing Approval for Shyndec Subsidiary's Drug Raw Materials
MT
China Production Bases of Shyndec Pharmaceutical's Unit Gets Compliance Certification from Australian Regulator
MT
Shyndec Pharma's Unit Gets Regulatory Nod for Sheep Vaccine
MT
Shyndec Pharma Unit's Cefotaxime Sodium for Injection Passes Drug Regulator's Consistency Evaluation
MT
Cancer Drug of Shyndec Pharma's Unit Passes Drug Regulator's Evaluation
MT
Shanghai Shyndec Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Shyndec Pharma Unit Obtains Antihistamine Marketing Rights for 7.7 Million Yuan
MT
China Grants Supplementary Drug Approval for Shyndec Pharmaceutical Subsidiaries' Antibiotic, Hypertension Tablets
MT
Shyndec Pharma Passes Drug GMP Compliance Inspection
MT
Shyndec Pharmaceutical's Drug Chosen for China's Centralized Bid
MT
Shyndec Pharmaceutical Unit's Cefprozil Tablets Passes Regulatory Evaluation
MT
Shanghai Shyndec Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023
CI
Shyndec Pharmaceutical's Unit Gets Nod for Lidocaine Hydrochloride's Listing
MT
Shanghai Shyndec Pharmaceutical Co., Ltd.(XSSC:600420) added to S&P Global BMI Index
CI
Shanghai Shyndec Pharma Gets Nod to Market Blood Sugar Drug Ingredient
MT
Shanghai Shyndec Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023
CI
Shyndec Pharmaceutical's Unit Gets Nod for Registration of Oprinone Hydrochloride Injection
MT
Shanghai Shyndec Pharma Chairman Resigns
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 600420 Stock
  4. News Shanghai Shyndec Pharmaceutical Co., Ltd.